SCHEMBL4535265

SCHEMBL4535265

N[C@@H](CCC(=O)NCCOCCOCC(=O)NCCOCCOC[C]=O)C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLP1R P43220 8/20 0.41
GRM8 O00222 1/20 0.36
GRM6 O15303 1/20 0.36
GRIN2D O15399 1/20 0.36
GRIN3B O60391 1/20 0.36
GSR P00390 1/20 0.36
CYP1A2 P05177 1/20 0.36
GRIK1 P39086 1/20 0.36
GRM5 P41594 1/20 0.36
GRIA1 P42261 1/20 0.36
GRIA2 P42262 1/20 0.36
GRIA3 P42263 1/20 0.36
SLC1A3 P43003 1/20 0.36
SLC1A2 P43004 1/20 0.36
SLC1A1 P43005 1/20 0.36
GRIA4 P48058 1/20 0.36
GRIN1 Q05586 1/20 0.36
GRIN2A Q12879 1/20 0.36
GRIK2 Q13002 1/20 0.36
GRIK3 Q13003 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22978957 1.00 GLP1R (0.41) GLP1RGRM8GRM6GRIN2DGRIN3B
SCHEMBL19599343 0.88 GLP1R (0.44) GLP1RGRM8GRM6GRIN2DGRIN3B
SCHEMBL21316645 0.88 GLP1R (0.50) GLP1RGRM8GRM6GRIN2DGRIN3B
SCHEMBL20652760 0.87 GLP1R (0.42) GLP1RGRM8GRM6GRIN2DGRIN3B
SCHEMBL19599417 0.87 GLP1R (0.42) GLP1RGRM8GRM6GRIN2DGRIN3B
SCHEMBL19599416 0.87 GLP1R (0.42) GLP1RGRM8GRM6GRIN2DGRIN3B
SCHEMBL19599351 0.87 GLP1R (0.42) GLP1RGRM8GRM6GRIN2DGRIN3B
SCHEMBL24652598 0.86 GLP1R (0.48) GLP1RGRM8GRM6GRIN2DGRIN3B
SCHEMBL22026448 0.86 GLP1R (0.46) GLP1RGRM8GRM6GRIN2DGRIN3B
SCHEMBL19135682 0.86 GLP1R (0.51) GLP1RGRM8GRM6GRIN2DGRIN3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2637698-B1 DOUBLE-ACYLATED GLP-1 DERIVATIVES NOVO NORDISK AS (DK) 2022-04-20 EP disclosed
US-9708383-B2 Double-acylated GLP-1 derivatives NOVO NORDISK A/S (DK) 2017-07-18 US disclosed
US-20130288960-A1 Double-Acylated GLP-1 Derivatives NOVO NORDISK A/S (DK) 2013-10-31 US disclosed
EP-2637698-A1 DOUBLE-ACYLATED GLP-1 DERIVATIVES Novo Nordisk A/S (DK) 2013-09-18 EP disclosed
WO-2012062803-A1 DOUBLE-ACYLATED GLP-1 DERIVATIVES NOVO NORDISK A/S (DK) 2012-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130288960-A1 Double-Acylated GLP-1 Derivatives GLP1R, VIP, IAPP GLP1R 1/4885GRM8 2101/4885GRM6 3381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.